Program
pivekimab sunirine
Also written as “Pivekimab Sunirine” and “IMGN632”.
Its studies are mostly in Leukemia, Myeloid, Acute · Blastic Plasmacytoid Dendritic Cell Neoplasm, led by AbbVie.
Furthest: phase 3, since May 6, 20264 company-led studies, 4 open or runningNext primary completion: Feb 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 44 open or running | phase 3since May 6, 2026 | Dec 21, 2017 | Feb 2027phase 2 · NCT04086264 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 21, 2017First study: phase 2 study in Blastic Plasmacytoid Dendritic Cell NeoplasmFirst studyNCT03386513 · 179 enrolled · United States, France, Germany and more
- Sep 9, 2019Phase 2 study in Leukemia, Myeloid, AcuteNCT04086264 · 218 enrolled · United States, France, Germany and more
- Dec 15, 2025Phase 1 study in Leukemia, Myeloid, AcuteNCT07306832 · 18 planned · United States, Australia, France and more
- May 6, 2026Phase 3 study in Leukemia, Myeloid, AcutePhase 3 reachedNCT07581002 · 660 planned · United States, Austria, France and more
Ahead
- Feb 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT04086264
- Apr 2028Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT07306832
- Jun 2032Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT07581002
TargetBeta
IL3RA →read by rule
“Interleukin-3 receptor subunit alpha binding agent”ChEMBL 37, by rule
Other programs on IL3RA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| relmapirazinrule | medibeacon | phase 3 | 8 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07581002Leukemia, Myeloid, Acute · United States, Austria, France and more | 3 | Recruiting | Jun 2032 | 660 |
| NCT07306832Leukemia, Myeloid, Acute · United States, Australia, France and more | 1 | Recruiting | Apr 2028 | 18 |
| NCT04086264Leukemia, Myeloid, Acute · United States, France, Germany and more | 2 | Active, not recruiting | Feb 2027 | 218 |
| NCT03386513Blastic Plasmacytoid Dendritic Cell Neoplasm · United States, France, Germany and more | 2 | Active, not recruiting | Oct 2, 2024 | 179 |
How it is read
Names in the registry
- “Pivekimab Sunirine”, 2 entries
- “IMGN632”, 2 entries
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 3 studies
- Blastic Plasmacytoid Dendritic Cell Neoplasm, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.